Center for Disease Analysis Q2 2012 Update

1. INTRODUCTION TO CENTER FOR DISEASE ANALYSIS
Q2 2012 Update
720-890-4848
www.c4da.com Trusted Partner from Data Gathering to Decision Mak ing

2. CDA Fact Sheet
• Founded in 2003, spun-out as an independent company in 2012
• Leading firm providing data, analysis and insight on disease economics
• Two partners (Homie Razavi, Andrew Levitch) prior experience at Merck,
Pharmacia, and Searle
• Representative sample of clients and partners:
» More than 5 of the top ten Pharma Companies
» Many other Pharma, Biotech and adjacent companies
» World Health Organization
• Approximately 10 full time employees and a network of experts
• Offices in Colorado and New Jersey
2

3. Our services are built on exceptional data, robust analyses and
relationships/contacts with local/international experts
• Rx and Epi based • Patient flow and
• Future event analysis segmentation
Market & • Key treatment drivers
Sales Epidemiology
Forecast
In-Depth
Research,
• Market Access • Disease burden
Analyses & Disease
• National Strategy Strategy modeling and analysis
Modeling Burden
• Cost Benefit Analysis • Impact of new
• Indication Strategy treatments on global
burden
» Sequence
» Backup & 2nd gen Cost
• Launch Strategy Burden
» Sequence
» Penetration
» Expansion • Cost burden modeling
• Financial/Operational and analysis
Consulting • Impact of prevention,
diagnosis & treatment on
cost burden
3

4. Q2 Update – Sample of what we have been working on
• Completed a multi-country epidemiology study on HCV to assess key factors on
patient flow.
• Developed multi-country/region market models and sales forecasts for
biosimilars.
• Provided strategic consulting to enable a pre-revenue diagnostic company to
evaluate the financial impact of several scenarios.
• Commenced a project to build a market access database (Polaris). It will
contain unique macro and micro level data that will provide valuable insights for
strategic decisions.
• Submitted an abstract for AASLD on The number of treated HCV infected
patients in the Americas, Europe, and Asia Pacific in 2004-2010.
• Prepared HCV Global burden of Disease modeling and analysis.
• Working to gain an understanding of the HCV treatment algorithm’s in key
markets by conducting interviews with KOL’s.
• Scheduling meetings with several Ministers of Health, primarily in emerging
markets to understand their disease priorities.
If you are interested in hearing more about the exciting work we are doing or how we may be able to help
your organization please contact us at 720-890-4848 or visit our website www.c4da.com.
4